Journal Information
Vol. 82. Issue 3.
Pages 269-274 (May - June 2016)
Share
Share
Download PDF
More article options
Visits
7119
Vol. 82. Issue 3.
Pages 269-274 (May - June 2016)
Original article
Open Access
Antioxidant therapy in the elderly with tinnitus
Efeito da terapia com antioxidantes sobre o zumbido em idosos
Visits
7119
José Fernando Polanskia,b,
Corresponding author
jfpolanski@gmail.com

Corresponding author.
, Alexandra Dezani Soaresa, Oswaldo Laércio de Mendonça Cruza,c
a Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil
b Hospital de Clínicas, Federal University of Paraná (UFPR), Curitiba, PR, Brazil
c Department of Otorhinolaryngology and Head and Neck Surgery, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil
This item has received

Under a Creative Commons license
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (4)
Table 1. Profile of individuals with complaints of tinnitus.
Table 2. Distribution of the presence of comorbidities reported by patients with complaints of tinnitus.
Table 3. Distribution of Tinnitus Handicap Inventory (THI) by degree of subjects with complaint of tinnitus, for placebo (P), Ginkgo biloba 120mg/day (GB), α-lipoic acid 60mg/day plus vitamin C 600mg/day (AA+VC), and papaverine hydrochloride 100mg/day plus vitamin E 400mg/day (PP+VE) groups, before and after treatment time points.
Table 4. Distribution of Tinnitus Handicap Inventory (THI) by score of subjects with complaint of tinnitus, for placebo (P), Ginkgo biloba 120mg/day (GB), α-lipoic acid 60mg/day plus vitamin C 600mg/day (AA+VC), and papaverine hydrochloride 100mg/day plus vitamin E 400mg/day (PP+VE) groups, before and after treatment time points.
Show moreShow less
Abstract
Introduction

Several approaches have been tried for the treatment of tinnitus, from cognitive-behavioral therapies and sound enrichment to medication. In this context, antioxidants, widely used in numerous areas of medicine, appear to represent a promising approach for the control of this symptom, which often is poorly controlled.

Objective

To evaluate the effects of antioxidant therapy for tinnitus in a group of elderly patients.

Methods

Prospective, randomized, double-blinded, placebo-controlled clinical trial. The sample consisted of 58 subjects aged 60 years or older, with a complaint of tinnitus associated with sensorineural hearing loss. These individuals completed the Tinnitus Handicap Inventory (THI) questionnaire before and after six months of therapy. The treatment regimens were: Ginkgo biloba dry extract (120mg/day), α-lipoic acid (60mg/day)+vitamin C (600mg/day), papaverine hydrochloride (100mg/day)+vitamin E (400mg/day), and placebo.

Results

There was no statistically significant difference between THI by degree (p=0.441) and by score (p=0.848) before and after treatment.

Conclusion

There was no benefit from the use of antioxidant agents for tinnitus in this sample.

Keywords:
Tinnitus
Antioxidants
Aged
Resumo
Introdução

Uma série de abordagens terapêuticas tem sido empregada no tratamento do zumbido, desde terapias cognitivo-comportamentais e de enriquecimento sonoro até terapias medicamentosas. Nesse contexto, os agentes antioxidantes, amplamente utilizados em diversas áreas da medicina, parecem representar uma perspectiva promissora para o controle desse sintoma, que muitas vezes tem um controle clínico insatisfatório.

Objetivo

Avaliar os efeitos da terapia com agentes antioxidantes sobre o zumbido em um grupo de pacientes idosos.

Método

Ensaio clínico prospectivo, randomizado, duplo-cego e controlado por placebo.A amostra composta de 58 indivíduos com 60 anos ou mais, com queixa clínica de zumbido associado à perda auditiva, do tipo neurossensorial, em graus variados. Esses indivíduos foram submetidos ao questionário THI (Tinnitus Handicap Inventory) antes e após 6 meses de uso da medicação. Os esquemas terapêuticos foram os seguintes: extrato seco de Ginkgobiloba (120mg/dia), ácido α-lipóico (60mg/dia)+vitamina C (600mg/dia), cloridrato de papaverina (100mg/dia)+vitamina E (400mg/dia) e placebo.

Resultados

O THI após o tratamento foi estatisticamente igual ao THI antes do tratamento, tanto em graus (p=0,441) quanto em escores (p=0,848).

Conclusão

Não se verificou benefício estatisticamente significativo com o uso de agentes antioxidantes para o zumbido dos indivíduos avaliados.

Palavra-chave:
Zumbido
Antioxidantes
Idoso
Full Text
Introduction

Tinnitus, whose prevalence is estimated at approximately 10% of the adult population, has repercussions and an impact on quality of life of the affected individuals, that varies from a slight perception without discomfort to an extreme compromise in quality of life.1

For those whose tinnitus has significant clinical impact, a number of therapeutic approaches have been described and employed, from cognitive-behavioral therapies and sound enrichment, to drug approaches. Some studies have shown favorable results, while others did not result in benefits.2 Various substances have been used and tested as drug treatments. Among them, antioxidants have appeared promising.2 Antioxidants encompass a wide range of substances whose primary function is the neutralization and clearance of free radicals, that is, because of their molecular configuration, result in being toxic and harmful to cells and tissues. With respect to the auditory system, the action of free radicals in cochlear physiology has been demonstrated experimentally.3–6 In the case of auditory disorders, antioxidants have been used in sudden deafness, to try to prevent ototoxicity, and for acute acoustic trauma,7,8 as well as in the approach to presbycusis, sometimes with conflicting results.9,10 In cases of tinnitus, probably the substance most widely used and studied currently is Ginkgo biloba, an herbal antioxidant. Associations of antioxidants, vitamins, and phospholipids administered to patients diagnosed with idiopathic tinnitus demonstrated relief of this condition and decreased serum levels of free radicals in a case series study.11

Thus, it was decided to test the effects of antioxidants on tinnitus in a group of elderly patients in a controlled clinical study.

Methods

The research project was submitted to the Ethics Committee on Institutional Research and approved under No. CEP 0723/10.

The research was registered with the International Clinical Trials platform of the World Health Organization at: http://apps.who.int/trialsearch/trial.aspx?trialid=ACTRN12610000667011.

The sample was composed of 58 male and female subjects aged 60 years or older with clinical complaints of tinnitus associated with a variable degree of sensorineural hearing loss confirmed by previous audiometric testing. These subjects were administered the Tinnitus Handicap Inventory (THI) questionnaire12 before and after medication use. THI is a scale that measures discomfort caused by tinnitus, with questions related to everyday annoyances and losses attributed to the symptom, defining a different numeric value for each affirmative or negative answer, or for partial agreement. The final sum (score) is framed by a gradation (degree), from 1 (slight, only perceived in quiet environments) to 5 (catastrophic). In the sample selection, subjects with known allergy to any substance to be tested or with clinical contraindications to the use of these substances were excluded. Anticoagulant users or subjects with coagulopathy, as well as diabetics, were also excluded from the sample.

The entire group was interviewed in detail about their medical history, and the data were recorded. Then, participants were asked to give information about hearing loss duration, use (or not) of hearing aids, hypertension, dyslipidemia, heart disease, thyroid disease, and osteoarthropathy, and also in men, benign prostatic hyperplasia. The subjects were also asked about possible exposure to ototoxic substances or noisy environments, i.e., an exogenous auditory risk. In addition, a clinical exam was performed, focused on otoscopy.

Patients were treated for a period of six months. They were allocated into four groups and treated with one of the following regimens: dry extract of G. biloba (120mg/day), α-lipoic acid (60mg/day) plus vitamin C (600mg/day), papaverine hydrochloride (100mg/day) plus vitamin E (400mg/day), and placebo (starch capsules). The substances were not identified by name in the containers into which they were packed, but rather through symbols defined by a professional who did not participate in the research, as a way of blinding investigators and patients. For distribution and randomization of participants, the resources available at http://www.randomization.com were used.

The statistical tests used in the analysis included Pearson's chi-squared test, Fisher's exact test (or its extension), and analysis of variance with parametric and non-parametric repeated measures. In all conclusions reached through the inferential analysis, the significance level α=5% was used.

Results

The general epidemiological data of the sample are listed in Table 1.

Table 1.

Profile of individuals with complaints of tinnitus.

Gender
Male  26  44.8% 
Female  32  55.2% 
Age (years)
Mean  72.6
Median  73.0
Minimum  60.0
Maximum  89.0
Standard deviation  6.6
Education
Illiterate  1.7% 
Literate  12.1% 
Elementary school  38  65.5% 
High school  10  17.2% 
College  3.4% 
Professional occupation
Retired  49  84.5% 
Unemployed  1.7% 
Employed  13.8% 
Smoking
No  53  91.4% 
Yes  8.6% 
Alcohol consumption
No  50  86.2% 
Yes  13.8% 
Number of medications
None  6.9% 
17  29.3% 
17  29.3% 
13.8% 
10.3% 
5.2% 
3.4% 
1.7% 

The most significant general clinical data of the sample are listed in Table 2.

Table 2.

Distribution of the presence of comorbidities reported by patients with complaints of tinnitus.

Hearing aid use
No  55  94.8% 
Yes  5.2% 
Systemic blood hypertension
No  20  34.5% 
Yes  38  65.5% 
Dyslipidemia
No  49  84.5% 
Yes  15.5% 
Heart disease
No  58  100.0% 
Yes  –  – 
Hypothyroidism
No  49  84.5% 
Yes  15.5% 
Osteoporosis
No  49  84.5% 
Yes  15.5% 
Arthropathy
No  52  89.7% 
Yes  10.3% 
Benign prostatic hyperplasia (among men)
No  22  84.6% 
Yes  15.4% 
Other comorbidities
No  38  65.5% 
Yes  20  34.5% 
Hearing loss time (years)
Mean  6.7
Median  5.0
Minimum  1.0
Maximum  25.0
Standard deviation  4.9
Hearing risk (exposure to occupational noise and to ototoxics)
No  52  89.7% 
Yes  10.3% 
Otoscopy
No distinctive factors  57  98.3% 
Bilateral tympanosclerosis  1.7% 

Table 3 lists the distribution of THI by degree for subjects with complaints of tinnitus, in the different groups and in the time points before and after treatment.

Table 3.

Distribution of Tinnitus Handicap Inventory (THI) by degree of subjects with complaint of tinnitus, for placebo (P), Ginkgo biloba 120mg/day (GB), α-lipoic acid 60mg/day plus vitamin C 600mg/day (AA+VC), and papaverine hydrochloride 100mg/day plus vitamin E 400mg/day (PP+VE) groups, before and after treatment time points.

  PGBAA+VCPP+VE
THI degree – before
53.8%  25.0%  23.1%  26.7% 
15.4%  41.7%  38.5%  53.3% 
7.7%  25.0%  7.7%  6.7% 
23.1%  –  –  30.8%  6.7% 
–  –  8.3%  –  –  6.7% 
Total  13  100.0%  12  100.0%  13  100.0%  15  100.0% 
THI degree – after
53.8%  25.0%  30.8%  26.7% 
23.1%  41.7%  38.5%  40.0% 
7.7%  8.3%  –  –  20.0% 
15.4%  16.7%  30.8%  6.7% 
–  –  8.3%  –  –  6.7% 
Total  13  100.0%  12  100.0%  13  100.0%  15  100.0% 

Table 4 lists the distribution of THI in scores for subjects with complaints of tinnitus, in the different groups and in the time points before and after treatment.

Table 4.

Distribution of Tinnitus Handicap Inventory (THI) by score of subjects with complaint of tinnitus, for placebo (P), Ginkgo biloba 120mg/day (GB), α-lipoic acid 60mg/day plus vitamin C 600mg/day (AA+VC), and papaverine hydrochloride 100mg/day plus vitamin E 400mg/day (PP+VE) groups, before and after treatment time points.

  GB  AA+VC  PP+VE 
THI score – before
n  13  12  13  15 
Mean  28.2  32.8  38.8  28.0 
Median  14.0  29.0  32.0  24.0 
Minimum–maximum  2–72  12–80  4–76  2–96 
Standard deviation  25.1  19.9  24.7  23.8 
THI score – after
n  13  12  13  15 
Mean  24.2  34.8  32.5  30.4 
Median  14.0  24.0  24.0  24.0 
Minimum–maximum  0–64  6–80  0–72  2–96 
Standard deviation  23.1  24.7  25.5  25.0 

Pearson's chi-squared test (p=0.848). THI before and THI after treatment, by score.

After statistical analysis, it was concluded that THI before treatment was statistically equivalent to THI after treatment, both by degree (p=0.441) and by score (p=0.848). Additionally, the inferential results revealed that the four treatment groups were statistically equivalent, both in THI expressed by degree (p=0.663) and by score (p=0.715).

Discussion

A number of antioxidants have been studied, showing positive effects in several clinical conditions.13–15 In this study, the choice of the selected substances was based on the evidence and descriptions in the literature, both in clinical and experimental research, and also on their availability in this community. Briefly, G. biloba can be described as an herbal medicine whose active pharmacological groups are flavonoids with antioxidant and vasodilator action, and terpene lactones, which act as antiplatelet agents.16 Originally, α-lipoic acid was considered as part of the vitamin B complex, but now is no longer considered as a vitamin, because there is evidence that this substance can be synthesized by the human body. α-Lipoic acid has an antioxidant effect and also an oxidative reduction effect on other antioxidants.14 Vitamin E is an essential fat-soluble vitamin whose main function is related to the lipid stability of cell membranes against oxygen free radicals. This vitamin also has a modulating effect on cell growth, in response to oxidative stress, hence its positive effect on atherosclerosis and certain neoplasms.17 Vitamin C or ascorbic acid is a water-soluble vitamin, critical for collagen and l-carnitine biosynthesis, for the conversion of dopamine to norepinephrine; it also improves iron absorption. Under physiological conditions, this vitamin also acts as a potent antioxidant.18 Papaverine hydrochloride is a synthetic alkaloid that exerts a tissue protective effect correlated to antioxidants, because this substance promotes non-specific smooth muscle relaxation, leading to vasodilation.19 Antioxidants act synergistically with other agents or in isolation, functioning in different ways, protecting cell membranes and also eliminating oxygen free radicals.4,6

The afflictions of the auditory apparatus are complex conditions that involve a number of physical phenomena, various tissues, and different topographies of the auditory pathway. Tinnitus appears to be caused by abnormal neural activity in cochlea–auditory cortex pathway.20 There is a consensus in the literature that at least some of the changes found along the auditory pathway and related to auditory symptoms appear to be related to biochemical changes, inflammation, and injuries induced by free radicals.8

The main cause of tinnitus is damage to hearing sensory cells of the cochlea, with or without association to an injury of central auditory system structures, through several etiopathogenic mechanisms.21 Subjects with normal hearing may also have tinnitus; however, patients with hearing loss may not have tinnitus. The sample of this study was entirely composed of subjects with tinnitus and sensorineural hearing loss.

With regard to the sample, anticoagulant users were excluded due to the chance of bleeding when these drugs are combined with G. biloba, which have an antithrombotic effect. Another group excluded was diabetics, due to the chance of glycemic imbalance when in combination with α-lipoic acid.14 Given the authors’ intention to test several substances in a very defined population group, the groups had a relatively limited number of subjects, but they were methodologically sound for this study and its statistical evaluation.

The substances chosen were processed in a compounding pharmacy, since the combinations used are not commercially available. This was also important in the blinding process, since the substances were packaged in identical capsules and identical bottles, but were identified by different symbols, so they could not be identified by the subjects or researchers. The person responsible for handling the substances was aware of this condition. The doses of substances used were based on what the literature recommends as an effective and clinically safe dose. In this study, there were no adverse effects with these substances during the study period and at the doses used. Moreover, according to the literature and pharmacological research, there are no reports on the associations of substances proposed in this study, nor information to indicate that, once associated, they could show decreased interaction or summation of their effects. This was corroborated by our results, since no modification of the researched symptom occurred after treatment.

The effects of antioxidant therapy for tinnitus were evaluated through THI,12 a validated and widely used questionnaire to evaluate the influence of tinnitus on quality of life of the subjects tested. As described earlier, there was no observable effect of the antioxidants on tinnitus in the sample groups for a period of six months. Some reports indicate that the use of B-complex vitamins could be beneficial in controlling tinnitus. However, no controlled clinical trial has proven this hypothesis.22 Regarding G. biloba in the treatment of tinnitus, a systematic review evaluating studies on the use of this substance (in its EGb 761 presentation) has demonstrated efficacy when compared to placebo.23 Another Cochrane group review conducted in 2013 did not demonstrate efficacy of G. biloba in the treatment of tinnitus, irrespective of the form in which the plant extract was obtained.24 The present study used compounded dry extract of G. biloba.

These findings also corroborate a recent international recommendation, against prescribing vitamin and dietary supplements for the treatment of patients with persistent and clinically relevant tinnitus.25

Conclusion

In the time interval and sample evaluated, we observed no statistically significant benefit from the use of antioxidants for tinnitus.

Conflicts of interest

The authors declare no conflicts of interest.

References
[1]
A. Davis, A. El Rafaie.
Epidemiology of tinnitus.
Tinnitus handbook, pp. 1-23
[2]
D. Baguley, D. McFerran, D. Hall.
Tinnitus.
Lancet, 382 (2013), pp. 1600-1607
[3]
W.J. Clerici, L. Yang.
Direct effects of intraperilymphatic reactive oxygen species generation on cochlear function.
Hear Res, 101 (1996), pp. 14-22
[4]
M.D. Seidman.
Effects of dietary restriction and antioxidants on presbycusis.
Laryngoscope, 110 (2000), pp. 727-738
[5]
A.A. Jacono, B. Hu, R.D. Kopke, D. Henderson, T.R. Van De Water, H.M. Steinman.
Changes in cochlear antioxidant enzyme activity after sound conditioning and noise exposure in the chinchilla.
Hear Res, 117 (1998), pp. 31-38
[6]
S.E. Heman-Ackah, S.K. Juhn, T.C. Huang, T.S. Wiedmann.
A combination antioxidant therapy prevents age-related hearing loss in C57BL/6 mice.
Otolaryngol Head Neck Surg, 143 (2010), pp. 429-434
[7]
H.Z. Joachims, J. Segal, A. Golz, A. Netzer, D. Goldenberg.
Antioxidants in treatment of idiopathic sudden hearing loss.
Otol Neurotol, 24 (2003), pp. 572-575
[8]
G.M. Haase, K.N. Prasad, W.C. Cole, J.M. Baggett-Strehlau, S.E. Wyatt.
Antioxidant micronutrient impact on hearing disorders: concept, rationale, and evidence.
Am J Otolaryngol, 32 (2011), pp. 55-61
[9]
M. Takumida, M. Anniko.
Radical scavengers for elderly patients with age-related hearing loss.
Acta Otolaryngol, 129 (2009), pp. 36-44
[10]
J.F. Polanski, O.L. Cruz.
Evaluation of antioxidant treatment in presbycusis: prospective, placebo-controlled, double-blind, randomised trial.
J Laryngol Otol, 127 (2013), pp. 134-141
[11]
M. Savastano, G. Brescia, G. Marioni.
Antioxidant therapy in idiopathic tinnitus: preliminary outcomes.
Arch Med Res, 38 (2007), pp. 456-459
[12]
C.W. Newman, G.P. Jacobson, J.B. Spitzer.
Development of the tinnitus handicap inventory.
Arch Otolaryngol Head Neck Surg, 122 (1996), pp. 143-148
[13]
T. Byers, B. Bowman.
Vitamin E supplements and coronary heart disease.
Nutr Rev, 51 (1993), pp. 333-336
[14]
A. Bilska, L. Wlodek.
Lipoic acid – the drug of the future?.
Pharmacol Rep, 57 (2005), pp. 570-577
[15]
S. Mahadevan, Y. Park.
Multifaceted therapeutic benefits of Ginkgo biloba L.: chemistry, efficacy, safety, and uses.
J Food Sci, 73 (2008), pp. 14-19
[16]
J.V. Smith, Y. Luo.
Studies on molecular mechanisms of Ginkgo biloba extract.
Appl Microbiol Biotechnol, 64 (2004), pp. 465-472
[17]
M. Meydani.
Vitamin E.
Lancet, 345 (1995), pp. 170-175
[18]
Y. Li, H.E. Schellhorn.
New developments and novel therapeutic perspectives for vitamin C.
J Nutr, 137 (2007), pp. 171-184
[19]
J.M. Mathis, M.E. Jensen, J.E. Dion.
Technical considerations on intra-arterial papaverine hydrochloride for cerebral vasospasm.
Neuroradiology, 39 (1997), pp. 90-98
[20]
J. Eggermont.
Pathophysiology of tinnitus.
Prog Brain Res, 166 (2007), pp. 19-35
[21]
D.M. Nondahl, K.J. Cruickshanks, G.H. Huang, B.E. Klein, R. Klein, F.J. Nieto, et al.
Tinnitus and its risk factors in the Beaver Dam offspring study.
Int J Audiol, 50 (2011), pp. 313-320
[22]
M.D. Seidman, R.T. Standring, J.L. Dornhoffer.
Tinnitus: current understanding and contemporary management.
Curr Opin Otolaryngol Head Neck Surg, 18 (2010), pp. 363-368
[23]
A. Von Boetticher.
Ginkgo biloba extract in the treatment of tinnitus: a systematic review.
Neuropsychiatr Dis Treat, 7 (2011), pp. 441-447
[24]
M.P. Hilton, E.F. Zimmermann, W.T. Hunt.
Ginkgo biloba for tinnitus.
Cochrane Database Syst Rev, 3 (2013), pp. CD003852
[25]
D.E. Tunkel, C.A. Bauer, G.H. Sun, R.M. Rosenfeld, S.S. Chandrasekhar, E.R. Cunningham, et al.
Clinical practice guideline: tinnitus.
Otolaryngol Head Neck Surg, 151 (2014), pp. 1-40

Please cite this article as: Polanski JF, Soares AD, de Mendonça Cruz OL. Antioxidant therapy in the elderly with tinnitus. Braz J Otorhinolaryngol. 2016;82:269–74.

Institution: Department of Otorhinolaryngology and Head and Neck Surgery, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil.

Copyright © 2015. Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial
Idiomas
Brazilian Journal of Otorhinolaryngology (English Edition)
Article options
Tools
en pt
Announcement Nota importante
Articles submitted as of May 1, 2022, which are accepted for publication will be subject to a fee (Article Publishing Charge, APC) payment by the author or research funder to cover the costs associated with publication. By submitting the manuscript to this journal, the authors agree to these terms. All manuscripts must be submitted in English.. Os artigos submetidos a partir de 1º de maio de 2022, que forem aceitos para publicação estarão sujeitos a uma taxa (Article Publishing Charge, APC) a ser paga pelo autor para cobrir os custos associados à publicação. Ao submeterem o manuscrito a esta revista, os autores concordam com esses termos. Todos os manuscritos devem ser submetidos em inglês.